Antifungal peptides, their screening methods and applications

By using machine learning to screen antifungal peptides with amino acid chain lengths of 17-50 from the gut microbiome, the problems of drug resistance and low R&D efficiency of traditional antifungal drugs have been solved, achieving efficient inhibition of a variety of fungi and low-cost development.

CN123106841APending Publication Date: 2026-11-17SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510615369.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing antifungal drugs face the problem of drug resistance. Traditional antibiotics are not very effective in treating fungal infections, and the development of new antifungal drugs is inefficient and costly, making it difficult to effectively address the growing threat of fungal infections.

Method used

Using machine learning methods, 36 antifungal peptides with amino acid chain lengths of 17-50 were screened from the gut microbiome of colorectal cancer patients. Their antifungal activity against a variety of pathogenic fungi was verified through in vitro antibacterial experiments, and a highly effective antifungal drug was developed.

Benefits of technology

It significantly inhibits fungi such as Candida auris, Candida tropicalis, Candida albicans, Cryptococcus neoformans, and Candida glabrata, exhibits high antifungal activity, is easy to synthesize, significantly shortens the identification cycle of antifungal peptides, reduces discovery costs, and improves the efficiency of antifungal drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106841A_ABST
    Figure CN123106841A_ABST
Patent Text Reader

Abstract

This invention discloses an antifungal peptide, its screening method, and its applications, belonging to the field of antimicrobial drug technology. This invention utilizes machine learning methods to identify antifungal peptides from the gut microbiota of healthy individuals and colorectal cancer patients, and then verifies the antibacterial or bactericidal activity of the peptides through in vitro antibacterial activity assays. Based on this method, this invention screened 36 antifungal peptides effective against Candida species. The amino acid chain lengths of these antifungal peptides are concentrated between 17 and 50, with small molecular weights, easy synthesis, and high antifungal activity, making them suitable for preparing antifungal drugs or other antimicrobial products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of antibacterial drug technology, specifically relating to an antifungal peptide, its screening method, and its application. Background Technology

[0002] Infectious diseases are a leading cause of death and disability worldwide. The World Health Organization estimates that drug-resistant bacterial infections directly cause 1.27 million deaths annually and indirectly cause approximately 4.95 million more, imposing a tremendous social and economic burden in resource-constrained environments. Currently, antibiotics are the primary treatment for infectious diseases; however, the overuse of antibiotics in recent years has led to the emergence of numerous multidrug-resistant organisms (MDROs), which can spread rapidly and cause increasingly difficult-to-treat infectious diseases, posing a serious threat to global public health security.

[0003] Compared to bacterial infections, fungal infections have always been a clinical challenge. Deep fungal and invasive fungal infections have high ICU mortality rates, with approximately 13.5 million people worldwide suffering from life-threatening Candida and mold infections each year, and the number of deaths increasing annually. Superficial fungal infections, on the other hand, tend to recur and are generally difficult to cure with medication.

[0004] Currently, among all antifungal drugs, only polyenes, flucytosine, azoles, and echinocandins are widely used in the treatment of fungal infections. However, all of these antifungal drugs have significant drawbacks: for example, amphotericin B has high nephrotoxicity; the main disadvantage of pyrimidine antifungals is the rapid development of resistance, with high toxicity including hepatotoxicity and hematologic toxicity; azoles have a high rate of resistance; and echinocandins are gradually losing their sensitivity to certain fungi. The problem of resistance to traditional antifungal drugs is becoming increasingly serious, and there is a lack of available preventative vaccines for fungal infections, posing a significant challenge to the future prevention and treatment of fungal infections.

[0005] Fungal infections pose a significant challenge to humans and global ecosystems. Developing novel antibiotics, probiotics, prebiotics, immunomodulators, and peptides are effective strategies for combating fungal infections. Some of these, including novel compounds synthesized through chemical synthesis, new structures targeting known targets, and modified versions of existing drugs, are currently undergoing preclinical and clinical trials as antifungal drug candidates. However, these novel antifungal drugs still face limitations in target discovery, clinical development, and safety assessment, requiring further in-depth research and clinical validation. Therefore, the continuous development of novel antifungal drugs to address the increasingly serious threat of fungal infections is crucial for global public health.

[0006] Short peptides have attracted widespread attention due to their high diversity, convenient synthesis, biodegradability, low toxicity, broad-spectrum antibacterial activity, and low likelihood of inducing drug resistance. In particular, a large number of antimicrobial peptides (AMPs) derived from bacteria can be used to treat bacterial, fungal, and viral infections, and even cancer, showing promise as a replacement for traditional antibiotics. However, current antimicrobial peptide drug development has certain limitations, such as long development time and low efficiency.

[0007] The development of artificial intelligence (AI) technology has accelerated drug discovery to some extent. With the advancement of computer technology and gene sequencing technology, machine learning is playing an increasingly important role in drug discovery. The gut microbiome possesses a high abundance and diversity of genes, making it one of the largest reservoirs of antibiotic resistance genes. Studies have shown extensive cross- and intra-domain interactions among the four kingdoms of the human gut microbiome, and the association between fungi and bacteria is enhanced in colorectal cancer patients. Therefore, in-depth analysis of the gut microbiome using AI technology holds promise for discovering potential antimicrobial drugs. Summary of the Invention

[0008] Therefore, this invention utilizes machine learning methods to identify antifungal peptides (AFPs) from the gut microbiome of colorectal cancer patients, and then detects and verifies the antifungal activity of these peptides through in vitro antibacterial activity experiments. Based on this method, this invention screened 36 antifungal peptides effective against Candida species. These antifungal peptides have amino acid chain lengths concentrated between 17-50, small molecular weights, are easy to synthesize, and exhibit high antifungal activity, achieving significant antibacterial effects even at extremely low concentrations of 2 μg / ml. They are effective against common clinical pathogenic fungi, such as Candida auris (…). Candida auris ), Tropical Candida ( Candida tropicalis ), Candida albicans ( Candida albicans Cryptococcus neoformans ( Cryptococcus neoformans , H99 ) and Candida glabrata ( Candida glabrata It exhibits a significant inhibitory effect. The antifungal peptide provided by this invention can be used to prepare antifungal drugs or other antibacterial products to exert an antifungal infection effect.

[0009] This invention provides the following technical solution: In a first aspect, the present invention provides an antifungal peptide, characterized in that the antifungal peptide is selected from at least one of the polypeptides shown in SEQ ID NO. 1-SEQ ID NO. 36: Table 1. Amino acid sequence information of antifungal peptides The fungus is selected from Candida auris ( Candida auris), Tropical Candida ( Candida tropicalis ), Candida albicans ( Candida albicans Cryptococcus neoformans ( Cryptococcus neoformans , H99 ) and Candida glabrata ( Candida glabrata At least one of the following.

[0010] In some embodiments of the present invention, the fungus is Candida auris ( Candida auris The anti-Candida auris ( Candida auris The antifungal peptide has at least one of the following structures: a1)X aa1 MKX aa2 RPSVKX aa3 X aa4 CX aa5 KCX aa6 X aa7 IX aa8 RX aa9 GX aa10 VMVICENPKHKQX aa11 QGX aa12 ; a2)MRVKITLACTECKQRNYNTX bb1 KNKKNX bb2 PDRLEMNKYCX bb3 FCX bb4 KHTX bb5 HX bb6 ETK; a3) MGKKLKKCLVELLKIFLL; (SY6) a4) MKKAKEKEGGKYGGLKNHTALLGKRRVCHYTDKRKIWKNNGAARLSIAV; (SY11) a5)MNEELVAAKKELFNLRFQNATNQLDNTSRIKEVRKNIARIQTVIAQKNA; (SY29) a6) MPGVRRMPGGGGTDGGGPEGEKCSGERVFDGEAETGYFGSGIAFGVAGCL; (SY35) a7) MPVHRNTNRFVIDILLKNLKKYKNTQFYILGCKKGCKSRKCLIYTLYCGE; (SY36) a8) MTRRSLKTLSVYHKTDTFGRKKRHFAQKCAISTLSAREG; (SY56) a9)MRFLRHPCFTIKNLRLWI; (SY62) a10)MKGALVSIICCIFANGFGYCHFQDIVGKQKHSLLFRVQPKASETYWK; (SY66) a11)MKVLKIPNSGTTDGLNKQKQGLKVVLKANDHGRFGKKDRSVED; (SY70) a12) MLFRKRNRVRGRKTTAPLYCGRSGNNGRWNCKGYSDTGSGCWRWKRL; (SY71) a13) MMNRKKIGSKRRQASRNISLGNPKKEAVKSLLLPLTRIIVPGKSTI. (SY72) In structure a1), X aa1 Existence or non-existence, when X aa1 When it exists, X aa1 Selected from MEVNS; X aa2 Selected from I or V; X aa3 Selected from P or K; X aa4 Selected from M or I; X aa5 Selected from E or D; X aa6 Selected from K or R; X aa7 Selected from I or V; X aa8 Selected from K or R; X aa9 Selected from K or H; X aa10 Selected from R, K, or H; X aa11 Selected from R or K; X aa12 Existence or non-existence, when X aa12 When it exists, X aa12 Selected from N.

[0011] In a specific embodiment of the present invention, structure a1) is selected from the following structures: a1-1) MEVNSMKVRPSVKPMCEKCKIIKRKGRVMVICENPKHKQRQG; (SY4) a1-2) MKVRPSVKKMCEKCKIIKRKGKVMVICENPKHKQRQG; (SY18) a1-3) MKVRPSVKPICEKCKVIKRKGHVMVICENPKHKQKQG; (SY22) a1-4) MKVRPSVKPMCDKCRIIRRKGRVMVICENPKHKQRQGN; (SY23) a1-5) MKVRPSVKPMCEKCKIIKRHGKVMVICENPKHKQRQG; (SY25) a1-6) MKIRPSVKPMCEKCRIIKRKGRVMVICENPKHKQKQG; (SY10) In structure a2), X bb1 Selected from K, M, or V, X bb2 Selected from D, S, or T, X bb3 Selected from K or R, X bb4 Selected from K or R, X bb5 Selected from L or V, X bb6 Selected from K or R.

[0012] In a specific embodiment of the present invention, structure a2) is selected from the following structures: a2-1) MRVKITLACTECKQRNYNTKKNKKNDPDRLEMNKYCKFCKKHTLHKETK; (SY45) a2-2) MRVKITLACTECKQRNYNTMKNKKNDPDRLEMNKYCRFCRKHTVHRETK; (SY47) a2-3) MRVKITLACTECKQRNYNTMKNKKNSPDLEMNKYCRFCKKHTLHKETK; (SY73) a2-4) MRVKITLACTECKQRNYNTVKNKKNTPDRLEMNKYCRFCRKHTLHKETK; (SY74) In a specific embodiment of the present invention, the anti-Candida auris ( Candida auris The antifungal peptide is selected from at least one of SY4, SY6, SY10, SY11, SY18, SY22, SY23, SY25, SY29, SY35, SY36, SY45, SY47, SY56, SY62, SY66, SY70, SY71, SY72, SY73, and SY74.

[0013] The anti-Candida auris ( Candida auris The amino acid sequence of the antifungal peptide is as follows: Table 2. Amino acid sequence information of antifungal peptides against Candida auris. In some embodiments of the present invention, the fungus is Candida tropicalis (… Candida tropicalis The anti-tropical Candida ( Candida tropicalis The antifungal peptide has at least one of the following structures: b1)X aa1 MKVRPSVKX aa2 X aa3 CX aa4KCX aa5 X aa6 IX aa7 RX aa8 GX aa9 VMVICENPKHKQRQG; b2) MAVVGKKRRSIRNCRTGKKTGRYTNHIGSKGISGTRKNIR; (SY2) b3) MTVKITLACTECKQRNYNTTKNKKNNPDRLEMKKYCRFCKKHTVHRETK; (SY58) b4) MCSDRGAHTKAALIGHIKNGKKSYNNRVKTWSFRLSKLQHLSKEKL; (SY3) b5) MSPAGWERWKSKYLVNLPGKNRIGRKMCYNNGNAHFPFCCLTGFAAA. (SY53) In structure b1), X aa1 Existence or non-existence, when X aa1 When it exists, X aa1 Selected from MEVNS; X aa2 Selected from P or K; X aa3 Selected from M or I; X aa4 Selected from E or D; X aa5 Selected from K or R; X aa6 Selected from I or V; X aa7 Selected from K or R; X aa8 Selected from K or N; X aa9 Selected from R or K.

[0014] In a specific embodiment of the present invention, structure b1) is selected from the following structures: b1-1) MEVNSMKVRPSVKPMCEKCKIIKRKGRVMVICENPKHKQRQG; (SY4) b1-2) MKVRPSVKKMCDKCKIIKRKGRVMVICENPKHKQRQG; (SY17) b1-3) MKVRPSVKPMCEKCKIIRRKGRVMVICENPKHKQRQG; (SY26) b1-4) MKVRPSVKKICDKCKVIKRNGKVMVICENPKHKQRQG; (SY15) b1-5) MKVRPSVKPICDKCRVIKRKGRVMVICENPKHKQRQG; (SY19) In a specific embodiment of the present invention, the anti-tropical Candida ( Candida tropicalis The antifungal peptide is selected from at least one of SY2, SY17, SY26, SY58, SY3, SY4, SY15, and SY19.

[0015] The anti-tropical Candida ( Candida tropicalis The amino acid sequence of the antifungal peptide is as follows: Table 3. Amino acid sequence information of antifungal peptides against Candida tropicalis. In some embodiments of the present invention, the fungus is Candida albicans (… Candida albicans The anti-Candida albicans ( Candida albicans The antifungal peptide has at least one of the following structures: c1)MX aa1 X aa2 X aa3 ITLACTECKQRNYX aa4 TX aa5 KX aa6 KKX aa7 TX aa8 PDRX aa9 EX aa10 X aa11 KYCX aa12 FCX aa13 KHTX aa14 HRETK; c2) MKVLKIPNSGTTDGLNKQKQGLKVVLKANDHGRFGKKDRSVED; (SY70) c3) MCPWHNCRGTLPHGRLKKKSKKEQYKCISNGITNRLRPIGNVRPRSWVRS; (SY61) c4) MKGALVSIICCIFANGFGYCHFQDIVGKQKHSLLFRVQPKASETYWK; (SY66) c5) MKKRYGFIYVDKDDQGNGSLKRYRKKSFYWYKKVIETNGQTKFE; (SY67) c6) MKNILIMLLELLILLILVKKI; (SY69) c7)MYKQQIKRLLFHMLMHLLKMKILKIKKYLFI. (SY77) In structure c1), X aa1 Selected from R or T; X aa2 Selected from T or V; X aa3Selected from R or K; X aa4 Selected from D or N; X aa5 Selected from M, T, or V; X aa6 Selected from D or N; X aa7 Selected from A or N; X aa8 Selected from H, N, or T; X aa9 Selected from M or L; X aa10 Selected from T or M; X aa11 Selected from S, K, or N; X aa12 Selected from K or R; X aa13 Selected from G, K, or R; X aa14 Selected from L or V.

[0016] In a specific embodiment of the present invention, structure c1) is selected from the following structures: c1-1) MRTRITLACTECKQRNYDTMKDKKAHPDRMETSKYCKFCGKHTLHRETK; (SY40) c1-2) MTVKITLACTECKQRNYNTTKNKKNNPDRLEMKKYCRFCKKHTVHRETK; (SY58) c1-3) MRVKITLACTECKQRNYNTVKNKKNTPDRLEMNKYCRFCRKHTLHKETK; (SY74) In a specific embodiment of the present invention, the anti-Candida albicans ( Candida albicans The antifungal peptide is selected from at least one of SY70, SY40, SY58, SY61, SY66, SY67, SY69, SY74, and SY77.

[0017] The anti-Candida albicans ( Candida albicans The amino acid sequence of the antifungal peptide is as follows: Table 4. Amino acid sequence information of antifungal peptides against Candida albicans. In some embodiments of the present invention, the fungus is Cryptococcus neoformans (… Cryptococcus neoformans , H99 The anti-cryptococcus neoformans ( Cryptococcus neoformans , H99 The antifungal peptide has at least one of the following structures: d1) MKVRPSVKPX aa1 CEKCKX aa2 IX aa3 RKGX aa4 VMVICENPKHKQX aa5 QG; d2)MRTRITLACTECKQRNYSTTKDKKVMPDRMEIKKYCKFCKSHTLHKETK; (SY42) d3) MTRRSLKTLSVYHKTDTFGRKKRHFAQKCAISTLSAREG; (SY56) d4)MNEELVAAKKELFNLRFQNATNQLDNTSRIKEVRKNIARIQTVIAQKNA. (SY29) In structure d1), X aa1 Selected from I or M; X aa2 Selected from V or I; X aa3 Selected from K or R; X aa4 Selected from H or R; X aa5 Selected from K or R.

[0018] In a specific embodiment of the present invention, structure d1) is selected from the following structures: d1-1) MKVRPSVKPICEKCKVIKRKGHVMVICENPKHKQKQG; (SY22) d1-2) MKVRPSVKPMCEKCKIIRRKGRVMVICENPKHKQRQG; (SY26) In a specific embodiment of the present invention, the anti-cryptococcus neoformans ( Cryptococcus neoformans , H99 The antifungal peptide is selected from at least one of SY22, SY26, SY42, SY56, and SY29.

[0019] The anti-cryptococcal ( Cryptococcus neoformans , H99 The amino acid sequence of the antifungal peptide is as follows: Table 5. Amino acid sequence information of antifungal peptides against Cryptococcus neoformans. In some embodiments of the present invention, the fungus is Candida glabrata (… Candida glabrata The anti-candidiasis ( Candida glabrata The antifungal peptide of ) has the following structure: MKVRPSVKPMCDKCRVIKRKGRVMVICENPKHKQRQG (SY24).

[0020] In a second aspect, the present invention provides a pharmaceutical composition comprising an effective dose of the antifungal peptide described in the first aspect of the present invention.

[0021] Furthermore, the pharmaceutical composition also includes pharmaceutically acceptable excipients.

[0022] In a preferred embodiment of the invention, the pharmaceutical composition is suitable for non-gastrointestinal administration, such as via intravenous, intramuscular, intradermal, and subcutaneous routes. Therefore, depending on the applicable dosage form, the pharmaceutically acceptable excipient is selected from antioxidants, buffers, antibacterial agents, suspending agents, solubilizers, or solutes that make the formulation isotonic with the blood of the subject.

[0023] In one specific embodiment of the present invention, the pharmaceutical composition is an injection administered to the subject via intravenous injection.

[0024] Thirdly, the present invention provides a method for screening the antifungal peptides described in the first aspect of the present invention based on machine learning methods, the method comprising the following steps: S1) Construct an open reading frame (ORF) prediction framework and use the ORF Finder to predict metagenomic data from colorectal cancer cohorts and healthy individuals to obtain the encoding ORF amino acid sequences; S2) Construct a machine learning model for accurate identification of antifungal peptides. Input the amino acid sequence obtained in step S1) into the model for prediction, screen amino acid sequences with high scores, and perform species annotation and peptide abundance assessment on the gut metagenomics. S3) Correlation analysis was performed on fungi and peptides present in more than 5% of the samples; S4) Cross-validate the initially screened amino acid sequences with the metaproteome dataset to screen for sequences with protein expression potential; S5) Synthesize peptides and use growth curves or plate colony counting methods to detect their antibacterial activity, and screen peptides with significant antibacterial effects as candidate antifungal peptides.

[0025] In step S1), the present invention uses BWA v0.7.17, samtools v1.17, bedtools v2.29.2, trim_galore v0.6.10, MEGAHIT v1.2.9, and ORF Finder to build an ORF prediction framework.

[0026] The model for accurately identifying antifungal peptides described in step S2) was constructed using the following method: S2.1) Collect antifungal peptide and non-antifungal peptide sequences as a dataset; S2.2) Clean and deduplicate the antifungal peptide and non-antifungal peptide data, and construct balanced and unbalanced datasets with various ratios based on sequence length (6-50 and 51-100), such as 1:1, 1:most class equal, and 1:2. S2.3) The training set consists of 80% of the samples randomly selected from the antifungal peptides (labeled 1) and the corresponding proportion of non-antifungal peptides (labeled 0), and the test set consists of the remaining 20% ​​of the samples; S2.4) The model was fine-tuned within the Protein Bert framework to adapt to the antifungal peptide classification task, resulting in the best-performing model for different length ranges.

[0027] This invention found that the training set constructed at a 1:1 ratio exhibits the best performance and prediction results.

[0028] The method for screening antifungal peptides provided by this invention can shorten the antifungal peptide development cycle, reduce discovery costs, and improve the efficiency of antifungal drug development.

[0029] Fourthly, the present invention provides the use of any of the following in inhibiting fungal growth and reproduction or in the preparation of antifungal products: (I) The antifungal peptide described in the first aspect of the present invention; and / or (II) The pharmaceutical composition according to the second aspect of the present invention.

[0030] The fungus is selected from Candida auris ( Candida auris ), Tropical Candida ( Candida tropicalis ), Candida albicans ( Candida albicans Cryptococcus neoformans ( Cryptococcus neoformans , H99 ) and Candida glabrata ( Candida glabrata At least one of the following.

[0031] The products are selected from pharmaceuticals, cosmetics, personal care products, food, food packaging, and antibacterial coatings.

[0032] In a specific embodiment of the present invention, the drugs include human medicines, veterinary drugs, and pesticides.

[0033] This invention overcomes the problems of traditional antimicrobial peptide design and synthesis, which rely on laboratories, are experimentally driven, time-consuming, labor-intensive, and inefficient. Based on an artificial intelligence drug screening system using natural language processing and deep learning, it identifies a group of antifungal peptides with significant inhibitory activity against Candida and Cryptococcus fungi, significantly shortening the antifungal peptide identification cycle, reducing discovery costs, and improving antibiotic development efficiency. Furthermore, the AI-based drug screening system provided by this invention will also discover more potential antifungal peptides in a shorter time. Attached Figure Description

[0034] Figure 1 Flowchart for screening antifungal peptides based on deep learning.

[0035] Figure 2 A diagram illustrating the distribution of the training dataset by length.

[0036] Figure 3 ORF-predicted distribution of antifungal peptide sequence lengths.

[0037] Figure 4 Length distribution of candidate antifungal peptides.

[0038] Figure 5 Comparison of similarity between candidate antifungal peptides and the model training set.

[0039] Figure 6 Comparison of the amino acid composition of candidate antifungal peptides with that of the model training set.

[0040] Figure 7 Comparison of the physicochemical properties of amino acids in candidate antifungal peptides and model training set.

[0041] Figure 8 Candidate antifungal peptides against Candida auris ( Candida auris The antifungal activity of the candidate antifungal peptides was detected, with the horizontal axis representing the concentration of the candidate antifungal peptides. "*" represents P≤0.05; "**" represents P≤0.01; "***" represents P≤0.001 (two-tailed T-test).

[0042] Figure 9 Candidate antimicrobial peptides against Candida tropicalis ( Candida tropicalis The antifungal activity of the candidate antifungal peptides was detected, with the horizontal axis representing the concentration of the candidate antifungal peptides. "*" represents P≤0.05; "**" represents P≤0.01; "***" represents P≤0.001 (two-tailed T-test).

[0043] Figure 10 Candidate antifungal peptides against Candida albicans ( Candida albicans The antifungal activity of the candidate antifungal peptides was detected, with the horizontal axis representing the concentration of the candidate antifungal peptides. "*" represents P≤0.05; "**" represents P≤0.01; "***" represents P≤0.001 (two-tailed T-test).

[0044] Figure 11 Candidate antimicrobial peptides against Candida glabrata ( Candida glabrata The antifungal activity of the candidate antifungal peptides was detected, with the horizontal axis representing the concentration of the candidate antifungal peptides. "*" represents P≤0.05; "**" represents P≤0.01; "***" represents P≤0.001 (two-tailed T-test).

[0045] Figure 12 Candidate antifungal peptides against Cryptococcus neoformans ( Cryptococcus neoformans The antifungal activity of the candidate antifungal peptides was detected, with the horizontal axis representing the concentration of the candidate antifungal peptides. "*" represents P≤0.05; "**" represents P≤0.01; "***" represents P≤0.001 (two-tailed T-test). Detailed Implementation

[0046] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0047] 1. Research Methods This invention uses deep learning to mine antifungal peptides (AFP) from the gut microbiome, and the process is as follows: Figure 1 As shown, it is divided into three parts: screening, identification, and validation. Specifically, it includes: the establishment of a gut microbiome metagenomic database of a multicenter population cohort and prediction of open reading frames (ORF) of the microbiome (Module 1); the establishment of a model for precise identification of antifungal peptides (Module 2); the assessment of the activity potential of candidate peptides and their species negative correlation screening system (Modules 3-4); the in vitro screening system (Module 5); and the in vivo screening system (Module 6).

[0048] 1.1 Establishment of a Gut Metagenomic Database This invention collected metagenomic data from eight colorectal cancer cohorts (PRJNA731589; PRJEB10878; PRJEB27928; PRJEB6070; PRJNA447983; PRJEB7774; PRJEB12449; PRJDB4176) and three healthy cohorts (PRJEB11532; PRJNA319574; SRP080787) worldwide, including 684 colorectal cancer patient samples and 2065 healthy human samples, for a total of 2749 intestinal metagenomic samples.

[0049] 1.2 Prediction of Open Reading Frames An open reading frame (ORF) is a DNA or RNA sequence that encodes a protein, extending from a start codon (usually AUG) to a stop codon (such as UAA, UAG, or UGA). To ensure the reproducibility and representativeness of our experimental results, the datasets included in this study exhibit broad geographical heterogeneity and diverse genetic backgrounds. Figure 2 This invention uses BWA v0.7.17, samtools v1.17, bedtools v2.29.2, trim_galore v0.6.10, MEGAHIT v1.2.9, and ORF Finder to build an ORF prediction framework. Figure 2Starting with metagenomic data from the human gut microbiome, after removing host DNA and adapters, the data were assembled de novo using MEGAHIT and predicted using ORF Finder to obtain the amino acid sequence.

[0050] 1.3 Model Construction for Precise Identification of Antifungal Peptides Existing antifungal peptides (AFP) and non-antifungal peptides (Non-AFP) were collected and merged into a fine-tuned dataset. The dataset has an imbalanced sequence length distribution, as shown in the following example. Figure 2 As shown, the data is grouped by length for training and prediction to ensure that the model does not predict whether a sequence is an antimicrobial peptide based on length features. After grouping the dataset into different length intervals, multiple balanced and imbalanced datasets are constructed. These datasets are then fed into a pre-trained model (Protein BERT) for fine-tuning to obtain the best-performing model for different length intervals. The score is the model's rating of the prediction results; the higher the value, the more reliable the prediction. This invention sets the model cutoff value to 0.95. Finally, the sequences are sorted according to their scores, with higher-scoring sequences being selected first.

[0051] This invention establishes balanced and unbalanced data models according to different proportions of data. The training set constructed with a 1:1 ratio exhibits the best performance and prediction effect.

[0052] The model for identifying antifungal peptides provided by this invention is optimized to eliminate the influence of sequence length on the model and enriches the prediction results. A higher cutoff value is set for the model's prediction results, selecting candidate antifungal peptides with higher scores, thus reducing computational cost. Table 6 shows a performance comparison between the model for identifying antifungal peptides provided by this invention and existing antimicrobial peptide models. The comparison results show that the model provided by this invention has higher accuracy and F1 score in identifying antifungal peptides.

[0053] Table 6 Performance comparison between the model of this invention and existing tools 1. LEE H, LEE S, LEE I, et al. AMP‐BERT: Prediction of antimicrobialpeptide function based on a BERT model [J]. Protein Science, 2022, 32(1). 2. SU X, XU J, YIN Y, et al. Antimicrobial peptide identification using multi-scale convolutional network [J]. BMC Bioinformatics, 2019, 20(1):730. 3. SANTOS-JúNIOR C D, PAN S, ZHAO X-M, et al. Macrel: antimicrobial peptide screening in genomes and metagenomes [J]. PeerJ, 2020, 8: e10555. 4. BHADRA P, YAN J, LI J, et al. AmPEP: Sequence-based prediction of antimicrobial peptides using distribution patterns of amino acid properties and random forest [J]. Scientific Reports, 2018, 8(1): 1697. 5. LI C, SUTHERLAND D, HAMMOND S A, et al. AMPlify: attentive deep learning model for discovery of novel antimicrobial peptides effective against WHO priority pathogens [J]. BMC Genomics, 2022, 23(1): 77. 6. FINGERHUT L C H W, MILLER D J, STRUGNELL J M, et al. ampir: an R package for fast genome-wide prediction of antimicrobial peptides [J]. Bioinformatics, 2021, 36(21): 5262-3. 1.4 Taxonomic annotation of gut microbiome species A custom annotation database was built using Jellyfish (v2.3.0) software, including the NCBI RefSeq database, FungiDB, and Ensemble database, and fungal species were annotated for 11 population cohorts using Kraken2 v2.1.3 software.

[0054] 1.5 Prediction of peptide abundance in the gut microbiome To obtain the abundance information of candidate antifungal peptides in each metagenomic sample, this invention uses Paladin software to perform antifungal peptide abundance analysis on 11 population cohorts.

[0055] 1.6 Correlation Analysis Spearman correlation analysis was performed on fungi and candidate peptides present in more than 5% of samples in each population cohort. The correlation was calculated using the CorAndPvalue (Spearman) function of the 'WGCNA' package in R and visualized using the Pheatmap package. Candidate AFPs were further screened based on correlation < 0 and P < 0.05. The analysis was performed in R (V4.2.3).

[0056] 1.7 Amino acid sequence evaluation The amino acid content of the peptide was calculated using the 'ProteinAnalysis' function of the 'Bio.SeqUtils.ProtParam' module in Biopython, and the analysis was performed in Python (V3.11.0). The physicochemical properties of the peptide were evaluated using the 'Peptides' package in R, and violin plots were drawn using 'ggplot2' in R.

[0057] 1.8 Peptide Synthesis The peptides used in this study were synthesized by Taopu and Jier Biochemicals, and their precise molecular weights were determined by mass spectrometry. The purity of all peptides was determined by high-performance liquid chromatography (HPLC), and the purity of all peptides was greater than 95%.

[0058] 1.9 Antibacterial activity assay ①Strain preservation: The strain is frozen in 30% glycerol and stored at -80℃ for later use; ②Preparation of YPD (Yeast Extract Peptone Dextrose) culture medium; ③ Bacterial strain resuscitation: Take 5 ml of 1X YPD liquid culture medium into a 15 ml centrifuge tube; take a small amount of cells and seed them into YPD liquid culture medium, and incubate overnight at 30℃ with a shaker at 180-200 rpm for 15 hours; ④ Determine strain density: After strain resuscitation, centrifuge at 3000 rpm for 2 minutes and discard the supernatant; wash twice with 1X PBS buffer and discard the supernatant; prepare a bacterial suspension using 2X YPD liquid medium to achieve an initial OD600 value of 0.04; prepare candidate antifungal peptide solutions of a certain concentration according to the experimental plan; add 75 μl of each peptide solution and 75 μl of bacterial suspension to a flat-bottomed 96-well plate; continuously monitor the plate at 30 ℃ for 24 hours, measuring OD every 15 minutes. 600 ; ⑤ Determine the number of strains: After continuous detection for 24 hours, perform culture omics. Determine the dilution factor for culture based on the strain density. Dilute to a suitable gradient using 1X PBS buffer, take 50 μl and plate it. After incubating the plate at 30 ℃ for 24 hours, perform statistical counting and plot the data using GraphPad Prism 8.

[0059] 2. Research Findings 2.1 Screening of candidate antifungal peptides This study completed ORF predictions for metagenomics in 11 population cohorts. The colorectal cancer group yielded 3,755,508,707 amino acid sequences, while the healthy controls group yielded 8,922,395,898 amino acid sequences. The predicted polypeptide sequence lengths were mainly distributed in the 6-50 amino acid range. Figure 3 Therefore, this study set the model prediction range to 6-50 and the cutoff value to 0.99, resulting in 10,819,929 candidate antifungal peptides (C_AFPs) in the colorectal cancer group and 21,884,138 candidate antifungal peptides in the healthy group, for a total of 27,533,632.

[0060] 2.2 Identification of candidate antifungal peptides While performing model predictions, this study also conducted species annotation and peptide abundance assessment of the gut metagenomics. After model predictions were completed, we performed correlation analysis on fungi and peptides present in more than 5% of samples from each population cohort. Considering that some peptides may exhibit different or even opposite correlations under different host states, we divided the population cohorts into a colorectal cancer group and a healthy group during the correlation analysis. We screened out peptides in each cohort that showed a statistically significant negative correlation with most fungi. The results showed that 4367 peptides were present only in the colorectal cancer group and 7082 peptides were present only in the healthy group. After removing completely repetitive sequences, a total of 16493 candidate antifungal peptides were obtained for further analysis.

[0061] Next, to ensure that the predicted ORF expression in bioinformatics represents protein / peptide, we performed cross-validation with a metaproteomics dataset. Using the PXD009056 and PXD038906 metaproteomics datasets, we cross-validated 16493 candidate antifungal peptides with 420 metaproteomics datasets using the Andromeda (MaxQuant) method to screen for candidate antifungal peptides with protein expression potential. The results showed that a total of 77 candidate antifungal peptides had expression potential, and the peptide length distribution is as follows: Figure 4 As shown, the lengths of the 77 polypeptides range from 17 to 50 AAs, with 37 AAs and 49 AAs being the most common.

[0062] Furthermore, this study evaluated the similarity between the candidate antifungal peptides and the model positive training set (which consisted of previously collected known AFP data). Figure 5-7 It is evident that the candidate antifungal peptides screened in this study showed less than 60% similarity to known datasets, and their amino acid compositions were not entirely similar. Furthermore, they exhibited low sequence similarity to antifungal peptides in the training set. These results not only demonstrate the efficiency and innovation of the designed process in generating antimicrobial peptides (AFPs), but also showcase its significant advantage in terms of diversity.

[0063] 2.3 Validation of candidate antifungal peptides This invention synthesized 70 candidate antifungal peptides and evaluated the antifungal activity of these 70 candidate antifungal peptides against 5 pathogenic fungi, namely: Candida albicans (… Candida albicans ), Candida glabrata ( Candida glabrata ), Candida auris ( Candida auris ), Tropical Candida ( Candida tropicalis Cryptococcus neoformans ( Cryptococcus neoformans , H99 ).

[0064] The five fungal strains were treated with a high concentration (500 μg / ml) of candidate antifungal peptides, and the peptides were screened in the first round based on the antifungal results. The initial screening results showed that the candidate antifungal peptides exhibited inhibitory effects on the five fungal strains, with varying inhibitory effects and antifungal activities against different fungi. Next, the inventors tested the antifungal activity of the candidate antifungal peptides with inhibitory effects at a low concentration (2 μg / ml). A total of 36 peptides with antifungal activity were obtained from 44 candidate peptides, and the amino acid sequences of these 36 peptides are shown in SEQ ID NO.1-SEQ ID NO.36.

[0065] The antibacterial data results of the 36 antifungal peptides are shown in Table 7.

[0066] Table 7 Antibacterial activity of antifungal peptides Based on the antibacterial activity data in Table 7, the following conclusions can be drawn: (1) There are 22 candidate antifungal peptides against Candida auris ( Candida auris All of them showed strong activity, namely SY4, SY6, SY10, SY11, SY18, SY22, SY23, SY25, SY29, SY35, SY36, SY45, SY47, SY56, SY62, SY66, SY70, SY71, SY72, SY73, and SY74. Figure 8 ).

[0067] (2) Nine candidate antifungal peptides were found to be effective against Candida tropicalis. Candida tropicalis The following exhibited strong antibacterial activity: SY2, SY17, SY26, SY58, SY3, SY4, SY15, and SY19. Figure 9 ).

[0068] (3) Nine candidate antifungal peptides were found to be effective against Candida albicans. Candida albicans The following exhibited strong antibacterial activity: SY70, SY40, SY58, SY61, SY66, SY67, SY69, SY74, and SY77. Figure 10 ).

[0069] (4) One candidate antifungal peptide is effective against Candida glabrata ( Candida glabrata It exhibits strong antibacterial activity and is SY24 ( Figure 11 ).

[0070] (5) Five candidate antifungal peptides are effective against Cryptococcus neoformans (Cryptococcus neoformans). Cryptococcus neoformans , H99 ) exhibited strong antibacterial activity, namely SY22, SY26, SY42, SY56, and SY29. Figure 12 ).

[0071] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. An antifungal peptide, characterized in that, The antifungal peptide is selected from at least one of the polypeptides shown in SEQ ID NO.1-SEQ ID NO.

36.

2. The antifungal peptide according to claim 1, characterized in that, The fungus is selected from at least one of Candida auris, Candida tropicalis, Candida albicans, Cryptococcus neoformans (H99), and Candida glabrata.

3. A pharmaceutical composition comprising an effective dose of the antifungal peptide of claim 1 or 2.

4. The pharmaceutical composition according to claim 3, characterized in that, The pharmaceutical composition also includes pharmaceutically acceptable excipients.

5. A method for screening the antifungal peptides of claim 1 or 2 based on machine learning methods, the method comprising the following steps: S1) Construct an ORF prediction framework and use ORF Finder to predict the amino acid sequences from metagenomic data of colorectal cancer cohorts and healthy individuals; S2) Construct a model for accurate identification of antifungal peptides. Input the amino acid sequence obtained in step S1) into the model for prediction, screen amino acid sequences with high scores, and perform species annotation and peptide abundance assessment on the gut metagenomics. S3) Perform correlation analysis on fungi and peptides present in more than 5% of the samples included in the cohort; S4) Cross-validate the initially screened amino acid sequences with the metaproteomics dataset to screen for sequences with protein expression potential; S5) Synthesize peptides and use fungi to test their antibacterial activity, and screen out peptides with significant antibacterial effects as antifungal peptides.

6. The method according to claim 5, characterized in that, In step S1), an ORF prediction framework is built using BWA v0.7.17, samtoolsv1.17, bedtools v2.29.2, trim_galore v0.6.10, MEGAHIT v1.2.9, and ORF Finder.

7. The method according to claim 5, characterized in that, The model for accurately identifying antifungal peptides described in step S2) was constructed using the following method: S2.1) Collect antifungal peptide and non-antifungal peptide sequences as a dataset; S2.2) Clean and deduplicatize the antifungal peptide and non-antifungal peptide data, and construct balanced and unbalanced datasets with various ratios based on sequence length (6-50 and 51-100), such as 1:1, 1:most class equal, and 1:

2. S2.3) The training set consists of 80% of the samples randomly selected from the antifungal peptides (labeled 1) and the corresponding proportion of non-antifungal peptides (labeled 0), and the test set consists of the remaining 20% ​​of the samples. S2.4) The model was fine-tuned within the Protein Bert framework to adapt to the antifungal peptide classification task, resulting in the best-performing model for different length ranges.

8. Any of the following applications in inhibiting fungal growth and reproduction or in the preparation of antifungal products: (I) The antifungal peptide according to claim 1 or 2; and / or (II) The pharmaceutical composition according to claim 3 or 4; The fungus is selected from at least one of Candida auris, Candida tropicalis, Candida albicans, Cryptococcus neoformans (H99), and Candida glabrata.

9. The application according to claim 8, characterized in that, The products are selected from pharmaceuticals, cosmetics, personal care products, food, food packaging, and antibacterial coatings.

10. The application according to claim 9, characterized in that, The medicines mentioned include human medicines, veterinary medicines, or pesticides.